Minimally Invasive Micro Sclerostomy: Safety and Preliminary Performance Study

Glaucoma Clinical Trial

Official title:

Minimally Invasive Micro Sclerostomy: First in Man (FIM) Safety and Preliminary Performance Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04484155
• Other study ID #: MMS-072-51
• Status: Completed
• Phase: N/A
• Start date: July 16, 2018
• Est. completion date: March 5, 2020

Study information

• Verified date: November 2022
• Source: Sanoculis Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Eligible Glaucoma patients will undergo pre-surgery examination including:

medicines list, blood tests and ECG. On surgery day: intraocular pressure (IOP) will be measured. Then a sub-conjunctival injection of Mitomycin C will be administered .

The Minimally Invasive Micro Sclerostomy (MIMS) procedure is designed to create a drainage channel at the sclera-corneal junction by penetrating through the wall [scleral tissue] . MIMS procedure may be combined with cataract surgery.

Patients will be followed up to 24 weeks post operation.

Description:

Eligible patients will have ECG and blood test up to 30 days prior to the MIMS procedure.

Description of MIMS procedure:

on surgery day, intraocular pressure (IOP) will be measured. Then a sub-conjunctival injection of Mitomycin C will be administered .

creating drainage channel at the sclera-corneal junction by penetrating through the wall [scleral tissue].MIMS procedure may be combined with cataract surgery.

Post-operatively the patient will be treated with dexamethasone-neomycin drops for at least one month.

Patients will be followed up to 24 weeks post operation.

The following measurements will be included:

• Intra Ocular Pressure (IOP)

• Best Corrected Visual Acuity (BCVA)

• Slit Lamp Biomicroscopic evaluation

• Anterior Segment Optical coherence tomography (OCT)

• Fundus Examination

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: March 5, 2020
• Est. primary completion date: March 2, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

Inclusion Criteria:

• Male or female = 18 years

• End stage Primary open-angle glaucoma,pseudoexfoliation glaucoma or pigmentary glaucoma in the study eye

• Optic nerve appearance characteristic of glaucoma in the study eye

• Best-corrected visual acuity (BCVA) with ETDRS charts = 6/60

• Patient is treated with 0 to 5 hypotensive medications in the study eye

• Unsatisfactory IOP (= 21 mmHg) at the screening visit in the study eye

• If cataract is not present - Shaffer grade = III in all four angle quadrants in the study eye

• Subject is able and willing to attend all scheduled follow-up exams

• Subject understands and signs the informed consent

Exclusion Criteria:

• Ocular conditions with a poorer prognosis in the fellow eye than in the study eye

• Closed angle forms of glaucoma in either eye unless scheduled for cataract surgery immediately prior to the MIMS procedure or the study eye is pseudophakic with PCIOL.

• Congenital or developmental glaucoma in either eye

• Other secondary glaucoma (such as neovascular, uveitic, lens-induced, trauma-induced, or glaucoma associated with increased episcleral venous pressure) in the study eye

• Peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities in the study eye

• Subject has history of penetrating keratoplasty (PKP)

• Any previous surgery in the study eye (except for clear corneal cataract surgery) where the conjunctiva is not intact and elastic.

• Any ocular disease or history in study eye such as severe dry eye, active proliferative retinopathy, ICE syndrome, epithelial or fibrous down growth, and ocular pathology that may interfere with accurate IOP measurements

• Prior surgery for an ab-interno or ab-externo device implanted in or through the Schlemm's canal in the study eye.

• Use of oral hypotensive medication for glaucoma for treatment of the fellow eye

• Best-corrected visual acuity worse than 20/50 (Snellen equivalent) in the fellow eye

• History of idiopathic or autoimmune uveitis in either eye

• Severe trauma in study eye

• active iris neovascularization, previous cyclodestructive procedure, prior scleral buckling procedure, presence of silicone oil

• Vitreous present in anterior chamber, prior vitrectomy or virteous hemorrhage in study eye

• Aphakia

• Prior vitreoretinal surgery in study eye

• Clinically significant ocular inflammation or infection within 90 days prior to screening

• Unable to discontinue use of blood thinners in accordance with surgeon's standard preoperative instructions

• Uncontrolled systemic disease that in the opinion of the investigator would put the subject's health at risk and/or prevent the subject from completing all study visits

• Current participation or participation in another investigational drug or device clinical trial within the last 30 days before screening visit

• Pregnant or lactating women

Related Conditions & MeSH terms

• Glaucoma

Intervention

Device:
• Minimally Invasive Micro Sclerostomy (MIMS)
The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.

Locations

Country	Name	City	State
India	Dr. Agarwal Eye Hospital Ltd.	Chennai

Sponsors (1)

Lead Sponsor	Collaborator
Sanoculis Ltd

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serious Adverse Event	Overall incidence of serious adverse events	12 weeks
Primary	Drainage Channel Creation	Ability to successfully perform a drainage channel	Index procedure day
Secondary	Serious Adverse Event	Overall incidence of serious adverse events	24 Weeks
Secondary	Intraocular Pressure	Intraocular Pressure between 6 mmHg and 20 mmHg	24 Weeks